Comments on: Elixir Raises $12 Million, Says Drug Trial Could Lead to Novartis Purchase http://www.xconomy.com/boston/2009/05/19/elixir-raises-12-million-says-drug-trial-could-lead-to-novartis-purchase/ Business + Technology in the Exponential Economy Sun, 22 Nov 2009 23:12:44 -0600 http://wordpress.org/?v=2.8.6 hourly 1 By: Getting a ghrelin drug to market « Science in the Triangle http://www.xconomy.com/boston/2009/05/19/elixir-raises-12-million-says-drug-trial-could-lead-to-novartis-purchase/comment-page-1/#comment-91105 Getting a ghrelin drug to market « Science in the Triangle Mon, 09 Nov 2009 00:31:09 +0000 http://www.xconomy.com/?p=25582#comment-91105 [...] Novartis is interested in a third experimental drug, Elixir’s oral ghrelin blocker that has shown to increase insulin sensitivity in animal studies. The Swiss drugmaker has an option to buy Elixir should tests in patients confirm the findings. A $12 million venture capital injection accompanied the Novartis deal. [...] [...] Novartis is interested in a third experimental drug, Elixir’s oral ghrelin blocker that has shown to increase insulin sensitivity in animal studies. The Swiss drugmaker has an option to buy Elixir should tests in patients confirm the findings. A $12 million venture capital injection accompanied the Novartis deal. [...]

]]> By: News, Money and Drugs for Tuesday, May 19, 2009 - Elton John Speaks at BIO!!! | IguanaBio - A Daily Biotech and Pharma Tabloid - Gossip, News, Research, Humor and Updates on the Latest Events in Biotech and Pharma - Unique, Insightful, Truthful, Sometimes http://www.xconomy.com/boston/2009/05/19/elixir-raises-12-million-says-drug-trial-could-lead-to-novartis-purchase/comment-page-1/#comment-59081 News, Money and Drugs for Tuesday, May 19, 2009 - Elton John Speaks at BIO!!! | IguanaBio - A Daily Biotech and Pharma Tabloid - Gossip, News, Research, Humor and Updates on the Latest Events in Biotech and Pharma - Unique, Insightful, Truthful, Sometimes Wed, 20 May 2009 00:28:07 +0000 http://www.xconomy.com/?p=25582#comment-59081 [...] Elixir Pharmaceuticals announced a $12M financing led by MPM Capital, also says it has granted Novartis an option to acquire the entire company following successful completion of a Phase 2 study with its ghrelin antagonist. [Xconomy] [...] [...] Elixir Pharmaceuticals announced a $12M financing led by MPM Capital, also says it has granted Novartis an option to acquire the entire company following successful completion of a Phase 2 study with its ghrelin antagonist. [Xconomy] [...]

]]>